{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107300","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.775528+00:00","generated_at":"2026-05-17T14:55:21.031814+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyverna Q2 net loss $42.1M, cash $211.7M; advances KYV-101 in SPS and MG","bullets":["Net loss $42.1M ($0.97/share) vs $28.8M in Q2 2024; R&D expenses rose to $35.8M from $27.3M.","Cash and equivalents $211.7M as of June 30, 2025, funding operations into 2027.","Phase 2 SPS registrational trial enrollment complete; topline data and BLA filing expected 1H 2026.","Phase 3 MG trial (~60 patients) enrollment to start by year-end 2025; interim Phase 2 data in Q4 2025.","Marc Grasso appointed CFO in June 2025; KYV-102 IND filing expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107300","json":"https://secwatch.observer/filing/0000950170-25-107300.json","markdown":"https://secwatch.observer/filing/0000950170-25-107300.md","text":"https://secwatch.observer/filing/0000950170-25-107300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/0000950170-25-107300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/kytx-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:55:21.031814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}